On Jan. 29, 2021, Innovation Pharmaceuticals announced that the companyﾒs Phase 2 clinical trial of Brilacidin for treating COVID-19 is scheduled to begin. The Phase 2 randomized, placebo-controlled clinical trial included approximately 120 hospitalized patients with moderate-to-severe COVID-19.